2BBBullish & Bearish
Exelixis, Inc. (EXEL) trades on NASDAQ. It operates in the Health Care sector, Biotechnology industry. Its current 2BB score is 62 out of 100.
Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.
Exelixis, Inc.’s current 2BB score is 62 out of 100, built from the signal categories below.
| Signal | Score | Reading |
|---|---|---|
| Activity | 67 | High |
| Momentum | 55 | Stable |
| Financial strength | 93 | Very Strong |
| Quality | 100 | Very Strong |
| Risk | 31 | Low |
| CEO | Michael M. Morrissey |
| Headquarters | Alameda, California, United States |
| Founded | Nov 15, 1994 |
| Employees | 1.08K |
| P/E ratio | 17.36 |
| 52-week range | $33.76 – $57.57 |
| Report date | EPS actual | EPS estimate | Revenue actual | Revenue estimate |
|---|---|---|---|---|
| 2027-02-08 | — | 0.8615 | — | $670.47M |
| 2026-11-02 | — | 0.8435 | — | $664.19M |
| 2026-08-05 | — | 0.8017 | — | $648.67M |
| 2026-05-05 | 0.79 | 0.7177 | $610.81M | $617.30M |